Interdisciplinary GU Cancer Forum 2025: The Role of ctDNA in Monitoring Patients with Metastatic Disease
Interdisciplinary GU Cancer Forum 2025, role of ctDNA in monitoring patients with metastatic disease, tumor-derived DNA, KEYNOTE-361 trial.
Related Articles
SNMMI 2025: STARLiT: Stereotactic Body Radiotherapy and 177Lu PSMA-617 in Locally Advanced Prostate Cancer
SNMMI 2025 STARLiT trial, stereotactic body radiotherapy (SBRT) plus 177Lu PSMA-617 in patients with locally advanced prostate cancer, ADT +/- abiraterone/prednisone.
The Use of PSMA PET/CT Improves Overall Survival in Men with Biochemically Recurrent Prostate Cancer Treated with Salvage Radiotherapy: Real-World Data from an Entire Country
International guidelines recommend salvage radiotherapy (sRT) as a curative treatment for men with biochemically recurrent prostate cancer after radical prostatectomy. Prostate-specific membrane antigen (PSMA) PET/CT…
PRECISION Data Platform Reveals mCRPC Treatment Outcomes in Urology Practices – Neal Shore
Zachary Klaassen interviews Neal Shore about real-world treatment patterns for mCRPC patients in community urology centers using the PRECISION database. Dr. Shore analyzes data from…
SNMMI 2025: A Combination of a CD46-Targeted Antibody-Drug Conjugate and a Radioimmunotherapy Agent for the Treatment of Prostate Cancer
SNMMI 2025, Prostate Cancer, Radioimmunotherapy Agent, CD46-Targeted Antibody-Drug Conjugate, CD46-Targeted Antibody-Drug Conjugate and a Radioimmunotherapy Agent for the Treatment of Prostate Cancer, anti-CD46 targeted antibody,…
Interdisciplinary GU Cancer Forum 2025: Novel Agents in Metastatic Urothelial Carcinoma
Interdisciplinary GU Cancer Forum 2025, Metastatic Urothelial Carcinoma, enfortumab vedotin, Nectin-4 antibody drug conjugate, CRB-701, BT8009-100, DURAVELO-1 trial, DURAVELO-2 trial, zelenectide pevedotin, pembrolizumab, zelenectide pevedotin…
Interdisciplinary GU Cancer Forum 2025: What is the Optimal Sequence of Treatment for Metastatic Urothelial Carcinoma?
Interdisciplinary GU Cancer Forum 2025, urothelial carcinoma, Metastatic Urothelial Carcinoma, enfortumab vedotin, advanced urothelial carcinoma when enfortumab vedotin, Optimal Sequence of Treatment for Metastatic Urothelial…
Interdisciplinary GU Cancer Forum 2025: The Role of ctDNA in Selecting Adjuvant Therapy Post-Cystectomy
Interdisciplinary GU Cancer Forum 2025, role of ctDNA in selecting adjuvant therapy post-cystectomy, pelvic lymph node dissection for invasive bladder cancer.
Interdisciplinary GU Cancer Forum 2025: New Approaches to Neoadjuvant Therapy for Urothelial Carcinoma
urothelial carcinoma, muscle invasive bladder cancer (MIBC), NIAGARA trial, perioperative immune checkpoint inhibitor, durvalumab, enfortumab vedotin, KEYNOTE-905/EV-303 trial, VOLGA trial.
Interdisciplinary GU Cancer Forum 2025: Clinical Trial Design for the Treatment of NMIBC
non muscle invasive bladder cancer (NMIBC), Bacillus Calmette-Guérin (BCG) therapy, BCG unresponsive disease.
Interdisciplinary GU Cancer Forum 2025: Novel Agents in NMIBC
Interdisciplinary GU Cancer Forum 2025, non muscle invasive bladder cancer (NMIBC), Novel Agents in NMIBC, EV-104 trial, SunRISe bladder trials, TAR-200, BOND-003 trial, CREST Trial,…